BioVie Stock (NASDAQ:BIVI)

Ownership Financials Chart

Previous Close

$2.08

52W Range

$1.04 - $33.10

50D Avg

$2.63

200D Avg

$3.73

Market Cap

$33.76M

Avg Vol (3M)

$6.14M

Beta

0.90

Div Yield

BIVI Company Profile

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Sep 18, 2020

Website

BIVI Performance

BIVI Financial Summary

	Jun 24	Jun 23	Jun 22
Revenue	-	-	-
Operating Income	$-32.18M	$-45.08M	$-27.25M
Net Income	$-33.01M	$-50.26M	$-26.08M
EBITDA	$-32.18M	$-44.29M	$-26.98M
Basic EPS	$-7.30	$-15.47	$-10.58
Diluted EPS	$-7.30	$-15.50	$-10.60

Fiscal year ends in Jun 24 | Currency in USD

Peer Comparison

Ticker	Company
DAWN	Day One Biopharmaceuticals, Inc.
HOOK	HOOKIPA Pharma Inc.
INZY	Inozyme Pharma, Inc.
XFOR	X4 Pharmaceuticals, Inc.
MREO	Mereo BioPharma Group plc
ELDN	Eledon Pharmaceuticals, Inc.
ABOS	Acumen Pharmaceuticals, Inc.
TERN	Terns Pharmaceuticals, Inc.
AMLX	Amylyx Pharmaceuticals, Inc.